Core Viewpoint - A class action lawsuit has been filed against V.F. Corporation, alleging securities fraud that negatively impacted shareholders between October 27, 2022, and May 20, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that V.F. Corporation made materially false and misleading statements regarding its turnaround plans, particularly concerning the Vans brand, which required significant reset actions to return to growth [3]. - The decline in Vans' growth trajectory was highlighted in V.F. Corporation's fiscal 2025 results, showing a drop from an 8% loss in the previous quarter to a 20% loss in the fourth quarter, with expectations of continued decline [4]. Group 2: Stock Impact - Following the disclosure of the disappointing results, V.F. Corporation's stock price fell from $14.43 per share on May 20, 2025, to $12.15 per share on May 21, 2025, marking a decline of approximately 15.8% in one day [4]. Group 3: Next Steps for Shareholders - Shareholders who experienced losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [5].

Core Viewpoint - A class action securities lawsuit has been filed against Cytokinetics, alleging securities fraud related to misleading statements about the New Drug Application (NDA) for aficamten, which affected investors between December 27, 2023, and May 6, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Cytokinetics made materially false and misleading statements regarding the expected timeline for FDA approval of aficamten, indicating approval in the second half of 2025 based on a September 26, 2025 PDUFA date [2]. - It is alleged that the company failed to disclose significant risks associated with not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [2]. - During an earnings call on May 6, 2025, it was revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [2]. Group 2: Investor Information - Investors who suffered losses during the relevant time frame have until November 17, 2025, to request the Court to appoint them as lead plaintiff, although participation does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Fluor Corporation is facing a class action securities lawsuit due to alleged securities fraud that occurred between February 18, 2025, and July 31, 2025, impacting investors adversely [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Fluor Corporation made false statements regarding the rising costs of its infrastructure projects, including Gordie Howe, I-635/LBJ, and I-35, which were attributed to subcontractor design errors, price increases, and scheduling delays [2]. - It is alleged that these issues, along with a reduction in customer capital spending and client hesitation due to economic uncertainty, were likely to have a significant negative impact on the Company's business and financial results [2]. - The financial guidance provided by Fluor for FY 2025 is claimed to be unreliable and unrealistic, with an overstated effectiveness of the Company's risk mitigation strategy and an understated impact of economic uncertainty on its business [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until November 14, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Participation in the class action does not require investors to incur any out-of-pocket costs or fees, allowing them to potentially receive compensation without financial obligation [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - Marex Group plc is facing a class action securities lawsuit due to alleged securities fraud that inflated its financial metrics, impacting investor trust and potential recovery [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between May 16, 2024, and August 5, 2025 [1]. - Defendants are accused of making false statements and concealing the improper inflation of cash flow, revenues, assets, and profits through off-book intercompany transactions [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4].

Core Viewpoint - A class action securities lawsuit has been filed against CarMax, Inc. for alleged securities fraud affecting investors between June 20, 2025, and September 24, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that defendants made false statements and concealed information regarding CarMax's growth prospects, claiming that the growth was overstated and primarily driven by temporary factors related to customer behavior influenced by tariff speculation [2]. - The lawsuit seeks to recover losses for investors who were adversely affected by these misleading statements during the specified time frame [1][2]. Group 2: Next Steps for Investors - Investors who suffered losses in CarMax, Inc. during the relevant period have until January 2, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to the efficacy of its drug Efzofitimod, which did not meet its primary endpoint in a recent study [2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for aTyr investors who were affected by alleged securities fraud between November 7, 2024, and September 12, 2025 [1]. - Defendants allegedly made positive statements about Efzofitimod while concealing material adverse facts regarding its efficacy, particularly its ability to allow patients to taper steroid usage [2]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a significant stock price drop from $6.03 to $1.02, a decline of 83.2% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until December 8, 2025, to request the Court to appoint them as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Points - A class action securities lawsuit has been filed against WPP plc, alleging securities fraud that affected investors between February 27, 2025, and July 8, 2025 [1] - The lawsuit claims that WPP misled investors by providing overly positive statements while concealing significant adverse facts about its media arm's performance and market share losses [2] - Following a trading update on July 9, 2025, which revealed a deterioration in performance, WPP's stock price dropped from $35.82 to $29.34, a decline of approximately 18.1% in one day [2] Case Details - The complaint highlights that WPP's media arm was not adequately equipped to handle macroeconomic challenges and was losing market share to competitors [2] - The company attributed its poor performance to macroeconomic uncertainties affecting client spending and weaker new business, compounded by ongoing restructuring efforts [2] Next Steps - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request appointment as lead plaintiff, although participation does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the United States [4]

Core Points - A class action securities lawsuit has been filed against Baxter International, Inc. for alleged securities fraud affecting shareholders between February 23, 2022, and July 30, 2025 [2][3] - The lawsuit claims that Baxter's Novum LVP product had systemic defects leading to serious patient risks, including underinfusion, overinfusion, and non-delivery of fluids [3] - Allegations include that Baxter was aware of multiple malfunctions and injuries but failed to implement adequate remedial measures, resulting in misleading statements about the product's safety and sales prospects [3] Company Details - Baxter International, Inc. is facing legal challenges due to claims of product defects in its Novum LVP, which could lead to significant financial repercussions for the company [3] - The lawsuit highlights the potential for Baxter to halt new sales of the Novum LVP and remove existing units from service, indicating a serious impact on the company's operations and reputation [3] Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, is representing the shareholders in this case, emphasizing their experience and success in similar lawsuits [5]

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for securities fraud following significant stock declines attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - The lawsuit is based on claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in DexCom securities [2]. - Investors have until December 26, 2025, to request to lead the case, which is pending in the U.S. District Court for the Southern District of New York [2]. Group 2: Product Issues - DexCom manufactures continuous glucose monitoring systems, including the G6 and G7, which were marketed as highly accurate [3]. - Allegations state that unauthorized design changes were made to the G6 and G7, compromising their accuracy and exposing users to health risks [4]. Group 3: Stock Performance - DexCom's stock experienced significant declines due to quality issues with the G6 and G7, including a drop of $7.12 per share (over 9%) following an FDA warning letter on March 7, 2025 [5]. - After the FDA published the warning letter on March 25, 2025, the stock fell another $3.19 per share (over 4%) [6]. - A report by Hunterbrook on September 18, 2025, revealed severe issues with the G7, leading to a nearly 12% drop of $8.99 per share [7].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 clinical trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational drug sonelokimab [3]. Clinical Trials and Data - The company conducted Phase 3 VELA trials for sonelokimab, claiming strong clinical data from its Phase 2 MIRA trial that suggested superior clinical responses compared to competitors [4]. - Allegations have emerged that the clinical data and the Nanobody structure of sonelokimab do not provide a superior clinical benefit over competitors, raising concerns about the drug's regulatory approval and commercial viability [5]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].